ContextVision (CONTX) Q2 2025 earnings summary

Executive summary

• Revenue declined 9.8% year-over-year to SEK 28.6 million in Q2 2025, mainly due to lower license sales in Asia and currency headwinds.

• Adjusted EBITDA for Q2 was SEK 5.1 million, with a margin of 17.8%.

• Strategic partnerships were signed with University of Waterloo, Inphase Solutions, and AMRA Medical to advance ultrasound diagnostics and digital biomarkers.

• Released a major Revent software upgrade and completed a new platform architecture for future clinically focused products.

• Achieved critical milestones in data quality and continued high customer interest in image quality solutions.

Financial highlights

• Q2 2025 revenue: SEK 28.6 million, down 9.8% year-over-year.

• Adjusted EBITDA: SEK 5.1 million, margin 17.8%.

• Net result: SEK 0.3 million, EPS: 0.00 SEK.

• Cash flow from operations: SEK 1.5 million.

• Cash and cash equivalents at end of Q2: SEK 70.4 million.

Outlook and guidance

• Short-term market conditions expected to remain uncertain due to global trade and supply chain disruptions, especially in Asia.

• Continued investment in R&D and Data Quality initiatives, with a clinical study on MASLD diagnostics launching soon.

• Confident in long-term growth strategy, focusing on image and data quality, with new product launches planned for fall 2025.